Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether a drug called regorafenib might be effective in
treating angiosarcoma. This study is for patients who have angiosarcoma that has gotten worse
after they received chemotherapy. Regorafenib is a type of drug called a kinase inhibitor.
Regorafenib interferes with how some kinase proteins work. Some of these kinases in cancer
cells might normally help the cancer cells grow or form new blood vessels that could feed a
growing tumor. By blocking these proteins, regorafenib may help stop the growth of certain
cancers.